During the corresponding time, Niagen Bioscience Inc saw a revenue deteriorated by -4.28 % year on year, sequentially revenue fell by -5.37 %. While revenue at the Niagen Bioscience Inc 's corporate clients
Niagen Bioscience Inc's Comment on Sales, Marketing and Customers
The company operates globally, serving customers in the dietary supplement, food and beverage, cosmetic, pharmaceutical, and life sciences industries. Its product offerings include small quantities of highly characterized phytochemicals, natural products, and plant-based materials used to ensure the quality of raw materials and finished products. The company also provides research services for natural product research and development. The pharmaceutical segment focuses on developing NAD+ precursors for therapeutic applications in advanced aging rare diseases, though it currently does not generate revenue. The addressable market includes the global wellness industry, personal care and beauty, healthy eating, nutrition and weight loss, traditional and complementary medicine, the spa market, the global dietary supplements market, and the intravenous hydration therapy market. No single customer accounted for more than 10% of net sales. Net sales increased from approximately $99.6 million in 2024 to $129.4 million in 2025. The company's segments included Consumer Products, Ingredients, and Analytical Reference Standards and Services, with the latter segment sold in 2026.
Niagen Bioscience Inc’s Comment on Sales, Marketing and Customers
The company operates globally, serving customers in the dietary supplement, food and beverage, cosmetic, pharmaceutical, and life sciences industries. Its product offerings include small quantities of highly characterized phytochemicals, natural products, and plant-based materials used to ensure the quality of raw materials and finished products. The company also provides research services for natural product research and development. The pharmaceutical segment focuses on developing NAD+ precursors for therapeutic applications in advanced aging rare diseases, though it currently does not generate revenue. The addressable market includes the global wellness industry, personal care and beauty, healthy eating, nutrition and weight loss, traditional and complementary medicine, the spa market, the global dietary supplements market, and the intravenous hydration therapy market. No single customer accounted for more than 10% of net sales. Net sales increased from approximately $99.6 million in 2024 to $129.4 million in 2025. The company's segments included Consumer Products, Ingredients, and Analytical Reference Standards and Services, with the latter segment sold in 2026.
Sources:
Niagen Bioscience Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Niagen Bioscience Inc’s corporate clients.
For your research, we’ve provided 9 tables on Niagen Bioscience Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.